```
=> d his

     (FILE 'HOME' ENTERED AT 14:59:03 ON 08 AUG 2007)

     FILE 'CAPLUS' ENTERED AT 14:59:21 ON 08 AUG 2007
L1             1 S US20060040920/PN
                 SELECT RN L1 1-

     FILE 'REGISTRY' ENTERED AT 14:59:35 ON 08 AUG 2007
L2            17 S E1-17
L3             7 S L2 AND 5-6-7/SZ
L4            10 S L2 NOT L3
L5             7 S L4 NOT (AMMONIA OR TRICHLORO OR PROPANONE)

     FILE 'CAPLUS' ENTERED AT 15:02:06 ON 08 AUG 2007
L6          2105 S L3

     FILE 'REGISTRY' ENTERED AT 15:03:27 ON 08 AUG 2007
L7             6 S L3 NOT 132539-06-1/RN
L8             1 S 132539-06-1/RN

     FILE 'CAPLUS' ENTERED AT 15:03:49 ON 08 AUG 2007
L9          2104 S L8
L10            2 S L7
L11       256096 S L5
L12           51 S L9 AND L11

=> d scan l8
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y
```

L8 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
MF C17 H20 N4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d ibib abs hitstr total l10

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:159389 CAPLUS
DOCUMENT NUMBER: 146:316350
TITLE: Crystal structure of olanzapine and its solvates. Part 3. Two and three-component solvates with water, ethanol, butan-2-ol and dichloromethane
AUTHOR(S): Wawrzycka-Gorczyca, Irena; Borowski, Piotr; Osypiuk-Tomasik, Joanna; Mazur, Liliana; Koziol, Anna E.
CORPORATE SOURCE: Faculty of Chemistry, Department of Crystallography, Maria Curie-Sklodowska University, Lublin, 20-031, Pol.
SOURCE: Journal of Molecular Structure (2007), 830(1-3), 188-197
CODEN: JMOSB4; ISSN: 0022-2860
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Crystalline solvates of olanzapine (1), 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, have been characterized by an X-ray anal. and thermal (DSC) data. Crystallization of 1 from ethanol gives a solid containing both water and ethanol mols.; the solvate 1·H2O·EtOH (2:2:1) is monoclinic with the space group P21/c and the unit-cell volume V = 3752.8(12) Å3. Butan-2-ol forms with 1 solvate which is also a three-component phase, 1·H2O·BuOH, but its stoichiometry is different (1:1:1). The space group for this crystal is P21/c and the unit-cell volume V = 2216.5(7) Å3. Crystalline olanzapine dichloromethane solvate (2:1), 1·CH2Cl2, is triclinic with the space group P.hivin.1. The characteristic feature of all crystal structures is presence of a pair of olanzapine mols. which form dimer stabilized by multiple weak C-H···π interactions between the N-methylpiperazine fragment and the Ph / thiophene systems. Theor. calcns. have been performed indicating that the total C-H···π binding energy is about 8 kcal mol-1. In the crystal structure, the self-assembled olanzapine mol. dimers are arranged into parallel crystal planes. Packing of the layers proceeds in two ways in which structural motives are replicated by (i) perpendicular translation forming columns, and (ii) rotation around the twofold screw axis (parallel to the layer).

IT 647826-03-7
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)
(crystallog. and thermal desolvation; crystal structure olanzapine two- and three-component solvates with water, ethanol, butan-2-ol and dichloromethane)

RN 647826-03-7 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, dichloromethane (2:1) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-09-2
CMF C H2 Cl2



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

appl.

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60321 CAPLUS
DOCUMENT NUMBER: 140:117363
TITLE: Preparation of polymorphic forms of olanzapine from its solvates
INVENTOR(S): Kotar, Jordan Berta; Vrecer, Franc; Grcman, Marija
PATENT ASSIGNEE(S): Krka, D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006933	A2	20040122	WO 2003-SI24	20030714
WO 2004006933	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21270	A	20040229	SI 2002-175	20020715
CA 2493370	A1	20040122	CA 2003-2493370	20030714
AU 2003256242	A1	20040202	AU 2003-256242	20030714
EP 1551414	A2	20050713	EP 2003-764287	20030714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006040920	A1	20060223	US 2005-521646	20050113
NO 2005000720	A	20050210	NO 2005-720	20050210
IN 2005CN00184	A	20070330	IN 2005-CN184	20050214
PRIORITY APPLN. INFO.:			SI 2002-175 A	20020715
			WO 2003-SI24 W	20030714

AB The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, a new polymorphic form A of olanzapine, and processes for the preparation thereof. For example, form A of olanzapine was prepared by suspending 10.0g olanzapine in 30 mL acetonitrile, adding 35mL methylene chloride in heated suspension, and drying under vacuum at 60OC.

IT 647825-99-8 647826-00-4 647826-01-5
647826-02-6 647826-03-7 647826-04-8
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)
(preparation of polymorphic forms of olanzapine from its solvates)

RN 647825-99-8 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, compd. with acetonitrile and dichloromethane, hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-09-2
CMF C H2 Cl2



CM 3

CRN 75-05-8
CMF C2 H3 N



RN 647826-00-4 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, compd. with acetonitrile (2:1), dihydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-05-8
CMF C2 H3 N



RN 647826-01-5 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, compd. with acetonitrile and dichloromethane (6:3:1), hexahydrate (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-09-2
CMF C H2 Cl2



CM 3

CRN 75-05-8
CMF C2 H3 N



RN 647826-02-6 CAPLUS
CN 2-Propanol, compd. with 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 67-63-0
CMF C3 H8 O



RN 647826-03-7 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, dichloromethane (2:1) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-09-2
CMF C H2 Cl2



RN 647826-04-8 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-, compd. with dichloromethane (6:1) (9CI) (CA INDEX NAME)

CM 1

CRN 132539-06-1
CMF C17 H20 N4 S



CM 2

CRN 75-09-2
CMF C H2 Cl2

$Cl-CH_2-Cl$

=> d ibib abs hitstr total l12

L12 ANSWER 1 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:819070 CAPLUS
TITLE: Novel polymorph E of olanzapine and preparation of anhydrous non-solvated crystalline polymorphic form I of 2-methyl-4(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5] benzodiazepine (olanzapine form i) from the polymorphic olanzapine form e
INVENTOR(S): Ray, Anup Kumar; V. Patel, Hiren Kumar; Ludescher, Johannes; Patel, Mahendra R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007173496	A1	20070726	US 2006-340284	20060126
WO 2007087555	A2	20070802	WO 2007-US60958	20070124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-340284 A 20060126

AB The invention provides an Olanzapine pseudopolymoph Form E. The invention provides methods of preparing polymorphic Olanzapine Form E employing rapid crystallization and seeding. The invention provides methods of preparing anhydrous Olanzapine Form I from the Olanzapine Form E by step-wise drying.

IT INDEXING IN PROGRESS
IT 67-63-0, Isopropanol 67-68-5, Dimethyl sulfoxide
75-09-2, Dichloromethane
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(polymorph E of olanzapine and preparation of anhydrous non-solvated crystalline polymorphic form I of 2-methyl-4(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5] benzodiazepine (olanzapine form I) from polymorphic olanzapine form E)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS

CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1P, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
(polymorph E of olanzapine and preparation of anhydrous non-solvated crystalline
polymorphic form I of 2-methyl-4(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5] benzodiazepine (olanzapine form I) from polymorphic olanzapine form E)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 2 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:761505 CAPLUS
DOCUMENT NUMBER: 147:150819
TITLE: Method for preparing a mixed solvate of olanzapine
INVENTOR(S): Dalmases Barjoan, Pere; Herbera Espinal, Reyes
PATENT ASSIGNEE(S): Inke, S.A., Spain
SOURCE: PCT Int. Appl., 17pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007077134	A1	20070712	WO 2006-EP70028	20061220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: ES 2006-59 A 20060105

AB An improved method is provided for preparing a mixed solvate of olanzapine/water/tetrahydrofuran in a proportion of 1:1:1/2. The improvement is characterized in that the mixed solvate is basically prepared by means of methylation of the N-desmethylolanzapine with di-Me sulfate, using THF and water as solvents.

IT 108-88-3, Toluene, uses 109-99-9, Tetrahydrofuran, uses
RL: NUU (Other use, unclassified); USES (Uses)
(method for preparing mixed solvate of olanzapine)

RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

IT 132539-06-1P, Olanzapine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(method for preparing mixed solvate of olanzapine)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:621955 CAPLUS
DOCUMENT NUMBER: 147:46090
TITLE: Induction of Cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro
AUTHOR(S): Hu, Wenyue; Sorrentino, Claudio; Denison, Michael S.; Kolaja, Kyle; Fielden, Mark R.
CORPORATE SOURCE: Iconix Biosciences, Mountain View, California, Department of Environmental Toxicology, University of California Davis, Davis, CA, USA
SOURCE: Molecular Pharmacology (2007), 71(6), 1475-1486
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Expression of Cyp1a1 and its related enzyme activity have long been used as a biomarker for aryl hydrocarbon receptor (AhR) activation and a warning of dioxin-like toxicity. As a result, induction of Cyp1a1 by pharmaceutical drug candidates or environmental contaminants raises significant concern in risk assessment. The current study evaluates the specificity of Cyp1a1 induction as a marker for AhR affinity and activation and provides context to assess the relevancy of AhR activation to risk assessment. In vivo expts. examined the expression of Cyp1a1 and other AhR-regulated genes in liver, kidney, and heart in response to 596 compds. From this data set, a subset of 147 compds. was then evaluated for their ability to activate or bind to the AhR using a combination of gel shift, reporter gene, and competitive receptor binding assays. Whereas in vivo Cyp1a1 mRNA expression is a sensitive marker for AhR activation, it lacks specificity, because 81 (59%) of 137 compds. were found to significantly induce Cyp1a1 in vivo but were not verified to bind or activate the AhR in vitro. Combining in vivo and in vitro findings, we identified nine AhR agonists, six of which are marketed therapeutics and have been approved by the U.S. Food and Drug Administration, including leflunomide, flutamide, and nimodipine. These drugs do not produce dioxin-like toxicity in rats or in humans. These data demonstrate that induction of Cyp1a1 is a nonspecific biomarker of direct AhR affinity and activation and lend further support to the hypothesis that Cyp1a1 induction and/or AhR activation is not synonymous with dioxin-like toxicity.

IT 68-12-2, N,N-Dimethylformamide, biological studies
132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(use of Cyp1a1 induction as nonspecific biomarker of aryl hydrocarbon receptor activation for screening of pharmaceuticals and toxicants)

RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:540907 CAPLUS
TITLE: Changing patterns of drug and alcohol use in fatally injured drivers in Washington state
AUTHOR(S): Schwilke, Eugene W.; Sampaio dos Santos, Maria Isabel; Logan, Barry K.
CORPORATE SOURCE: Forensic Laboratory Services Bureau, Washington State Patrol, Washington State Toxicology Laboratory, Seattle, WA, 98134, USA
SOURCE: Journal of Forensic Sciences (2006), 51(5), 1191-1198
CODEN: JFSCAS; ISSN: 0022-1198
PUBLISHER: Blackwell Publishing, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have previously reported on patterns of drug and alc. use in fatally injured drivers in Washington State. Here we revisit that population to examine how drug use patterns have changed in the intervening 9 years. Blood and serum specimens from drivers who died within 4 h of a traffic accident between Feb. 1, 2001, and Jan. 31, 2002, were analyzed for illicit and therapeutic drugs and alc. Drugs when present were quantitated. Samples suitable for testing were obtained from 370 fatally injured drivers. Alc. was detected above 0.01 g/100 mL in 41% of cases. The mean alc. concentration for those cases was 0.17 g/100 mL (range 0.02-0.39 g/100 mL). Central nervous system (CNS) active drugs were detected in 144 (39%) cases. CNS depressants including carisoprodol, diazepam, hydrocodone, diphenhydramine, amitriptyline, and others were detected in 52 cases (14.1%), cannabinoids were detected in 47 cases (12.7%), CNS stimulants (cocaine and amphetamines) were detected in 36 cases (9.7%), and narcotic analgesics (excluding morphine which is often administered iatrogenically in trauma cases) were detected in 12 cases (3.2%). For those cases which tested pos. for alc. c. 40% had other drugs present which have the potential to cause or contribute to the driver's impairment. Our report also considers the blood drug concns. in the context of their interpretability with respect to driving impairment. The data reveal that over the past decade, while alc. use has declined, some drug use, notably methamphetamine, has increased significantly (from 1.89% to 4.86% of fatally injured drivers) between 1992 and 2002. Combined drug and alc. use is a very significant pattern in this population and is probably overlooked in DUI enforcement programs.

IT INDEXING IN PROGRESS
IT 108-88-3, Toluene 132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
(pattern changes of drug and alc. use in fatally injured drivers in Washington state)
RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:538023 CAPLUS
DOCUMENT NUMBER: 146:507833
TITLE: Process for the preparation of olanzapine for dosage forms
INVENTOR(S): Kovanyine Lax, Gyoergyi; Nemeth, Gabor; Krasznai, Gyoergy; Mesterhazy, Norbert; Nagy, Kalman; Vereczkeyne Donath, Gyoergyi; Szent-Kirallyi, Zsuzsanna
PATENT ASSIGNEE(S): Egis Gyogyszergyar Nyrt., Hung.
SOURCE: PCT Int. Appl., 41pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054750	A2	20070518	WO 2006-HU96	20061110

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: HU 2005-1046 A 20051111

AB The invention relates to a process for the preparation of olanzapine by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride with N-methylpiperazine in an organic solvent having good phys. properties and suitable in respect of environmental and labour safety consideration, i.e., a mixture of toluene and 1,3-dimethyl-2-imidazolidinone. The invention also encompasses novel olanzapine dihydrochloride trihydrate, the preparation thereof and pharmaceutical compns. comprising the novel compound

IT 132539-06-1P, Olanzapine
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of olanzapine using aminomethylthienobenzodiazepine for dosage forms)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of olanzapine using aminomethylthienobenzodiazepine for dosage forms)
RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



L12 ANSWER 6 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:484935 CAPLUS
DOCUMENT NUMBER: 146:468572
TITLE: Organic nanoparticles and associated methods
INVENTOR(S): Farr, Isaac; Cartagena, Julio
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007098802	A1	20070503	US 2005-263725	20051031

PRIORITY APPLN. INFO.: US 2005-263725 20051031

AB Methods of preparing organic nanoparticles are provided. Such methods can include generating a mixture of an organic material, a first liquid, and a second liquid, wherein the organic material is more soluble in the second liquid than in the first liquid The methods can also include adding a third liquid to the mixture which causes the mixture to form an emulsion. Such an emulsion can have a continuous phase including the first liquid and a discontinuous phase including the organic material and the second liquid The organic material can be precipitated to form organic nanoparticles and the second liquid can diffuse into the continuous phase. A 0.5% mixture of 5 mg/mL of glyburide in 70% ethanol and 30% chloroform by weight was prepared To this mixture, water was added until clouding is observed at which point the emulsion has formed. Light scattering and SEM show the resulting nanoparticle size is on average about 500 nm. A few large nanoparticles may be observed of up to 1 to 3 μm.

IT 75-09-2, Methylene chloride, uses
RL: NUU (Other use, unclassified); USES (Uses)
(organic nanoparticles and associated methods)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(organic nanoparticles and associated methods)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L12 ANSWER 7 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:328200 CAPLUS
DOCUMENT NUMBER: 146:344231
TITLE: Organic acid salts of olanzapine and their preparation
INVENTOR(S): Kozluk, Thomasz
PATENT ASSIGNEE(S): Pol.
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007032695	A1	20070322	WO 2006-PL25	20060504

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: PL 2005-377084 A 20050915

AB New salts which comprise salts of olanzapine and carboxylic acids selected from the group consisting of: maleic acid, fumaric acid, phthalic acid, benzoic acid, salicylic acid or acetylsalicylic acid, of olanzapine to acid ratio of 1:1, 1:2 or other are prepared New salts of olanzapine and monoesters of dicarboxylic acids obtained in reaction of olanzapine with anhydrides selected from the group consisting of maleic anhydride, phthalic anhydride and succinic anhydride are presented. Synthesis of new olanzapine salts comprises carrying out the reaction of olanzapine in organic solvents with the carboxylic acids. NMR, X-ray diffraction and IR data are given for the salts.

IT 67-63-0, Isopropanol, processes
RL: PEP (Physical, engineering or chemical process); PROC (Process)
(carboxylic acid salts of olanzapine and their preparation)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: RCT (Reactant); RACT (Reactant or reagent)
(carboxylic acid salts of olanzapine and their preparation)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:265943 CAPLUS
DOCUMENT NUMBER: 146:380021
TITLE: Preparation and application of Olanzapine intermediate
INVENTOR(S): Tang, Chaojun; Yao, Chengzhi; Jia, Cunchao
PATENT ASSIGNEE(S): Hangzhou Shengmei Pharmaceutical Co., Ltd., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1923834	A	20070307	CN 2006-10053509	20060911
PRIORITY APPLN. INFO.:			CN 2006-10053509	20060911
OTHER SOURCE(S):	CASREACT 146:380021			

GI



I

AB The title Olanzapine intermediate has a general formula I (R = C1-C6 alkyl, C6-C18 aryl, heteroaryl, or benzyl). This Olanzapine intermediate can be used to prepare Olanzapine with the advantages of high Olanzapine yield, safe operation, low pollution on environment, etc.

IT 67-63-0, Isopropanol, uses 67-68-5, DMSO, uses
68-12-2, DMF, uses 75-09-2, Methylene chloride, uses
108-88-3, Toluene, uses 109-99-9, THF, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation and application of Olanzapine intermediate)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

IT 132539-06-1P, Olanzapine
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and application of Olanzapine intermediate)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L12 ANSWER 9 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:181157 CAPLUS
DOCUMENT NUMBER: 146:507560
TITLE: Hydrated form of olanzapine and process for preparation thereof
INVENTOR(S): Reguri, Buchi Reddy; Chakka, Ramesh
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India
SOURCE: Indian Pat. Appl., 18pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2002MA00496	A	20050304	IN 2002-MA496	20020701
PRIORITY APPLN. INFO.:			IN 2002-MA496	20020701

AB The object of the present invention is to provide the novel crystalline forms of olanzapine monohydrate. The present invention also provides a process for the preparation of novel olanzapine monohydrate. The process for the preparation of these hydrated forms comprises the dissoln. of crystalline Form of olanzapine in a mixture of water and an alc. using trifluoroacetic acid and further adjusting the pH of the mass towards basic with a known base to afford the hydrated forms of olanzapine. The present process is simple, eco-friendly and well suited for industrial scale up.

IT 67-63-0, Isopropanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(hydrated form of olanzapine and process for preparation thereof)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(hydrated form of olanzapine and process for preparation thereof)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L12 ANSWER 10 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1005866 CAPLUS
DOCUMENT NUMBER: 145:363423
TITLE: Process for preparing crystalline form I of olanzapine
INVENTOR(S): Sundaram, Venkataraman; Pandurang, Sharat Narsapur; Dayaram, Vishal Parmar; Bommareddy, Siva Kumar Reddy; Sitaram, Hitendra Chaudhary
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Ltd., India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006102176	A2	20060928	WO 2006-US9911	20060320
WO 2006102176	A3	20070118		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2005-CH291 A 20050321
US 2005-677115P P 20050503

no us yet

AB A process for preparing olanzapine Form I comprises: cooling a concentrated solution of olanzapine; isolating wet crystals of olanzapine Form I; and drying wet crystals and recovering olanzapine Form I. Drying can be conducted by stepwise increases in the drying temps., with extended holding times at each temperature condition. Olanzapine monohydrate was mixed with methylene chloride and the suspension was heated to obtain a clear solution and the resultant solution was filtered through a perlite bed in a and the filtrate was vacuum distilled to give the crystalline form I of olanzapine.

IT 75-09-2, Methylene chloride, uses
RL: NUU (Other use, unclassified); USES (Uses)
(process for preparing crystalline form I of olanzapine)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(process for preparing crystalline form I of olanzapine)
RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 11 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:980087 CAPLUS
DOCUMENT NUMBER: 145:342506
TITLE: Controlled release implant comprising biocompatible polymer for ocular delivery
INVENTOR(S): Dadey, Eric; Lindemann, Christopher M.; Warren, Stephen L.; Norton, Richard L.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 36pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006210604	A1	20060921	US 2005-244438		20051004
PRIORITY APPLN. INFO.:			US 2004-615727P	P	20041004
			US 2004-628630P	P	20041117
			US 2004-629133P	P	20041118

AB The present invention provides a flowable composition suitable for use as a controlled-release implant. The flowable composition can be administered into the ocular region of a mammal. The composition includes: (a) a biodegradable, biocompatible thermoplastic polymer that is at least substantially insol. in aqueous medium, water or body fluid; (b) a biol. agent, a metabolite thereof, a biol. agent acceptable salt thereof, or a prodrug thereof; and (c) a biocompatible organic liquid, at standard temperature and pressure, in which the thermoplastic polymer is soluble The present invention also provides methods of medical treatment that include administering the flowable composition into the ocular region of a mammal. For example, Atrigel intravitreal injection was prepared containing poly(lactide-co-glycolide) 15% in PEG.

IT 67-68-5, Methyl sulfoxide, biological studies 68-12-2, Dimethylformamide, biological studies 109-99-9, Tetrahydrofuran, biological studies 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release implant comprising biocompatible polymer for ocular delivery)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS

CN Furan, tetrahydro- (CA INDEX NAME)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 12 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:817672 CAPLUS
DOCUMENT NUMBER: 145:249105
TITLE: Preparation of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine monohydrochloride as a histamine H3 receptor ligand.
INVENTOR(S): Raga, Manuel, M.; Sallares, Juan; Guerrero, Marta; Guglietta, Antonio
PATENT ASSIGNEE(S): Ferrer Internacional, S. A., Spain
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006084833	A1	20060817	WO 2006-EP50703	20060206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1690858	A1	20060816	EP 2005-100942	20050210
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.: EP 2005-100942 A 20050210

AB 1-[3-[3-(4-Chlorophenyl)propoxy]propyl]-piperidine hydrochloride (I) was prepared Thus, Na 3-piperidinopropanolate, 3-(4-chlorophenyl)propyl mesylate, and 15-crown-5 were refluxed together in PhMe to give 75% 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine. The latter in EtOAc was treated with gaseous HCl at 20-25° followed by cooling to -10° to -12° to precipitate I. The product was recrystd. from EtOAc/iPrOH to give 80% I. I showed binding affinity to human recombinant histamine H3 receptors with Ki = 1.0 nM.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of chlorophenylpropoxypropylpiperidine monohydrochloride as a histamine H3 receptor ligand)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, Isopropanol, uses 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of chlorophenylpropoxypropylpiperidine monohydrochloride as a histamine H3 receptor ligand)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:795811 CAPLUS
DOCUMENT NUMBER: 145:235791
TITLE: Method and device for ophthalmic administration of active pharmaceutical ingredients
INVENTOR(S): Gross, Yossi; Herzog, Rafi; Koevary, Steven B.
PATENT ASSIGNEE(S): Pharmalight Inc., USA
SOURCE: PCT Int. Appl., 127pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006082588	A2	20060810	WO 2006-IL145	20060206
WO 2006082588	A3	20070104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-650144P P 20050207
US 2005-742870P P 20051207

no US yet

AB Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and a carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterilizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered drug in a pharmaceutical composition

IT 67-63-0, 2-Propanol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 68-12-2, N,N-Dimethylformamide, biological studies 109-99-9, Tetrahydrofuran, biological studies 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method and device for ophthalmic administration of pharmaceutical ingredients)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 14 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:548123 CAPLUS
DOCUMENT NUMBER: 145:14805
TITLE: An improved process for the preparation of polymorph form-I of olanzapine
INVENTOR(S): Giridhar, Thota; Reguri, Buchi Reddy; Chakka, Ramesh
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Limited, India
SOURCE: Indian, 15 pp.
CODEN: INXXAP
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 190857	A1	20030830	IN 2000-MA569	20000724

PRIORITY APPLN. INFO.: IN 2000-MA569 20000724

AB The present invention is related to a method for the preparation of polymorph form-I of olanzapine by conversion of the Form II into the desired polymorph by using CH2Cl2 as the solvent. Crude olanzapine was suspended in CH2Cl2 to give a clear solution and the resultant solution was then treated with carbon followed by filtration. The product obtained on drying was the polymorph form-I of olanzapine.

IT 75-09-2, Methylene chloride, uses
RL: NUU (Other use, unclassified); USES (Uses)
(improved process for preparation of polymorph form-I of olanzapine)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(improved process for preparation of polymorph form-I of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 15 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:434951 CAPLUS
DOCUMENT NUMBER: 146:50520
TITLE: The retention behavior of some atypical antipsychotic drugs in normal-phase TLC
AUTHOR(S): Skibinski, Robert; Misztal, Genowefa; Komsta, Lukasz; Korolczyk, Agata
CORPORATE SOURCE: Department of Medicinal Chemistry, Medical University of Lublin, Lublin, 20-090, Pol.
SOURCE: Journal of Planar Chromatography--Modern TLC (2006), 19(107), 73-80
CODEN: JPCTE5; ISSN: 0933-4173
PUBLISHER: Research Institute for Medicinal Plants
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Chromatog. behavior in normal-phase thin-layer chromatog. has been investigated for six atypical antipsychotic drugs (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone). The drugs were separated on silica gel, alumina, NH2, CN, diol, and polyamide plates with mixts. of n-hexane and six polar modifiers (acetone, dioxane, diethylamine, ethanol, isopropanol, and tetrahydrofuran) as mobile phases. The linearity of relationships between RM and volume fraction of modifier, the logarithm of the volume fraction, the molar fraction, and the logarithm of the molar fraction was tested. The results usually fitted the Snyder-Soczewinski equation, with r > 0.9. The best separation was achieved on silica gel plates with ethanol-n-hexane, 1+1 (volume/volume), containing 1.5% aqueous ammonia, as mobile phase.

IT 132539-06-1, Olanzapine
RL: ANT (Analyte); ANST (Analytical study)
(retention behavior of some atypical antipsychotic drugs in normal-phase TLC)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, Isopropanol, analysis 109-99-9, Tetrahydrofuran, analysis
RL: ARU (Analytical role, unclassified); ANST (Analytical study)
(retention behavior of some atypical antipsychotic drugs in normal-phase TLC)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:269740 CAPLUS
DOCUMENT NUMBER: 144:299489
TITLE: Processes for the preparation of olanzapine
INVENTOR(S): Pandya, Bhargav R.; Aryan, Ram Chander; Kumar, Yatendra
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006030300	A2	20060323	WO 2005-IB2749	20050916
WO 2006030300	A3	20060601		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2004-DE1762 A 20040917
IN 2004-DE1765 A 20040917

AB The invention relates to processes for the preparation of a crystalline polymorphic form of olanzapine. More particularly, it relates to the preparation of a crystalline polymorphic form of olanzapine designated as Form X and to pharmaceutical compns. that include the polymorphic Form X. The invention also relates to a process for the preparation of a methanol solvate of olanzapine and a process for using such solvate.

IT 67-63-0, Isopropanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(processes for the preparation of olanzapine polymorphs)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(processes for the preparation of olanzapine polymorphs)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(CA INDEX NAME)



L12 ANSWER 17 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:234837 CAPLUS
DOCUMENT NUMBER: 144:299584
TITLE: A novel process for preparation of a pharmaceutically pure polymorphic Form I of olanzapine
INVENTOR(S): Muthukumaran, Ganesan; Veeramani, Kaliyappan; Mullaiyur, Radhakrishnan Selvaraju; Porchezhiyan, Vedapuri; Kanagasalam, Selvaraj; Nazir, Kassim Khan; Chanidran, T.
PATENT ASSIGNEE(S): Shasun Chemicals and Drugs Limited, India
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006027800	A1	20060316	WO 2005-IN298	20050905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2004CH00898	A	20070622	IN 2004-CH898	20040906
PRIORITY APPLN. INFO.:			IN 2004-CH898 A	20040906

AB The invention is directed to a novel method for making crystalline Form I of olanzapine, wherein crude olanzapine is dissolved in a water-miscible solvent in which it is freely soluble, from which substantially pure polymorphic Form I of olanzapine is recovered by precipitation For example, 35 kg of crude olanzapine was dissolved in 105 L of DMSO, maintained at 50° for 30 min, and the solution was then filtered to remove the insolubles. Addnl. 35 L of DMSO was charged into the reactor, and press the washings through filter into another reactor. The filtrate was cooled to 40°, 350 L methanol was added slowly while maintaining the temperature between 40 and 50°, followed by slow addition of 105 L of water while maintaining the temperature between 40 and 50° to precipitate olanzapine completely from the solution The reaction mass was cooled to 0 to 5°, maintained for 3 h at the same temperature, filtered and then dried at 60 to 70° in a fluidized bed drier to obtain 25 kg of final product. The product was identified as substantially pure Form I of olanzapine by powder X-ray anal.

IT 67-68-5, Dimethyl sulfoxide, processes 68-12-2, Dimethylformamide, processes 109-99-9, Tetrahydrofuran, processes
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(preparation of pure polymorphic Form I of olanzapine)

RN 67-68-5 CAPLUS

CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation of pure polymorphic Form I of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:149063 CAPLUS
DOCUMENT NUMBER: 144:212809
TITLE: Process for preparing olanzapine via methylation of N-demethylolanzapine in dichloromethane and/or methanol.
INVENTOR(S): Venkataraman, Sundaram; Rajan, Srinivasan Thirumalai; Bulusu, Veera Venkata Naga Chandra Sekhar; Kasturi, Ravi Kumar; Kapabalu, Suneel Kumar; Gokavalasa, Kavitha
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Limited, India
SOURCE: U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2006035887	A1	20060216	US 2005-171093		20050630
PRIORITY APPLN. INFO.:			US 2004-585198P	P	20040702

OTHER SOURCE(S): CASREACT 144:212809
AB A process for preparing olanzapine comprises methylation of N-demethylolanzapine with a methylating agent in a solvent comprising CH2Cl2, MeOH, or a mixture thereof. Thus, N-demethylolanzapine (preparation given) in CH2Cl2 at <0° was treated with Me2SO4 and then with NaOH in MeOH at 0-5° to give olanzapine of 99.8% purity.
IT 132539-06-1P, Olanzapine
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(process for preparing olanzapine via methylation of N-demethylolanzapine in dichloromethane and/or methanol)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 75-09-2, Dichloromethane, uses
RL: NUU (Other use, unclassified); USES (Uses)
(process for preparing olanzapine via methylation of N-demethylolanzapine in dichloromethane and/or methanol)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)

$Cl-CH_2-Cl$

L12 ANSWER 19 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:117133 CAPLUS
DOCUMENT NUMBER: 144:198861
TITLE: Mixed solvate of olanzapine, method for preparing it and method for preparing form I of olanzapine therefrom
INVENTOR(S): Dalmases Barjoan, Pere; Bessa Bellmunt, Jordi
PATENT ASSIGNEE(S): Laboratorios Lesvi, S.L., Spain
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013435	A1	20060209	WO 2005-IB2209	20050707
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2253091	A1	20060516	ES 2004-1850	20040727
EP 1773841	A1	20070418	EP 2005-759149	20050707
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: ES 2004-1850 A 20040727
WO 2005-IB2209 W 20050707

AB Said mixed solvate is a solvate of olanzapine/water/tetrahydrofuran in the proportion 1:1:1/2 (I). The method for preparing said solvate comprises treating a crude anhydrous olanzapine with a mixture of tetrahydrofuran/water. The method for preparing Form I of olanzapine includes desolvating the mixed solvate of formula I, by means of drying, in vacuo and under temperature-controlled conditions.

IT 109-99-9, Tetrahydrofuran, reactions 132539-06-1, Olanzapine
RL: RCT (Reactant); RACT (Reactant or reagent)
(mixed solvate of olanzapine and method for preparing form I of olanzapine therefrom)

RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006024365	A1	20060202	US 2005-134633	20050519
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122
US 2004096499	A1	20040520	US 2003-630446	20030729

PRIORITY APPLN. INFO.:

IN 2002-MU697	A	20020805
IN 2002-MU699	A	20020805
IN 2003-MU80	A	20030122
IN 2003-MU82	A	20030122
US 2003-630446	A2	20030729

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 67-63-0, Isopropyl alcohol, biological studies 67-68-5, Dimethyl sulfoxide, biological studies 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 21 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:54122 CAPLUS
DOCUMENT NUMBER: 144:150401
TITLE: A process for the preparation of olanzapine
INVENTOR(S): Shastri, Jwalant Ashesh; Bhatnagar, Akshat; Thaper, Rajesh Kumar; Dubey, Sushil Kumar
PATENT ASSIGNEE(S): Jubilant Organosys Limited, India
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006180	A1	20060119	WO 2004-IN207	20040714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2576862	A1	20060119	CA 2004-2576862	20040714
EP 1778649	A1	20070502	EP 2004-745138	20040714
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: WO 2004-IN207 W 20040714
OTHER SOURCE(S): CASREACT 144:150401
GI



I

AB A process for the preparation of title compound I was disclosed. For example, a solution of 2-(2-aminoanilino)-5-methylthiophene-3-carbonitrile (10.0 g), N-methylpiperazine (60 mL) and N-methylpiperazine hydrochloride (24 gm)

was heated at 120 °C until the reaction was completed to afford after work olanzapine. Of note, 2-polymorphic forms of olanzapine were isolated.

IT 132539-06-1P, Olanzapine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphic forms I, II; preparation of olanzapine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-68-5, Dimethyl sulfoxide, uses 68-12-2, Dimethylformamide, uses 75-05-8, Acetonitrile, uses 75-09-2, Dichloromethane, uses 108-88-3, Toluene, uses 109-99-9, Tetrahydrofuran, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of olanzapine)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)

RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 22 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1311702 CAPLUS
DOCUMENT NUMBER: 144:57525
TITLE: Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
INVENTOR(S): Wilson, Michelle; Desai, Kishorkumar J.; Pauletti, Giovanni M.; Antoon, Mitchell K.; Clendening, Chris E.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. Ser. No. 126,863
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005276836	A1	20051215	US 2005-180076	20050712
US 6197327	B1	20010306	US 1998-79897	19980515
US 6086909	A	20000711	US 1999-249963	19990212
US 6572874	B1	20030603	US 2000-626025	20000727
NZ 508130	A	20020301	NZ 2000-508130	20001113
AU 765269	B2	20030911	AU 2001-54192	20010703
US 2003049302	A1	20030313	US 2002-226667	20020821
US 6982091	B2	20060103		
US 2004005345	A1	20040108	US 2003-349029	20030122
US 6905701	B2	20050614		
US 2004043071	A1	20040304	US 2003-600849	20030620
US 2005249774	A1	20051110	US 2005-126863	20050510

PRIORITY APPLN. INFO.:

US 1997-49325P	P	19970611
US 1998-79897	A2	19980515
US 1999-249963	A2	19990212
US 2000-626025	A2	20000727
US 2002-226667	A2	20020821
US 2003-349029	A2	20030122
US 2003-600849	A2	20030620
US 2004-587454P	P	20040712
US 2005-126863	A2	20050510
AU 1998-76976	A3	19980610
NZ 1998-502120	A1	19980610
US 1999-146218P	P	19990728
US 2001-315877P	P	20010829
US 2002-390748P	P	20020621

AB Disclosed is a vaginal device for delivering therapeutical and/or health-promoting agents. The vaginal device partly or completely coated by, covered by or combined with a coating or covering comprising a film, foam, strip, cap, cup or particles. The coating of the device comprises a mucoadhesive composition comprising a therapeutical and/or health-promoting agent. For example, sumatriptan vaginal suppository were prepared from Suppocire AS2X, hydroxypropyl Me cellulose as a mucoadhesive agent, and Transcutol as a permeation enhancer.

IT 67-68-5, Dimethyl sulfoxide, biological studies
132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 23 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1220824 CAPLUS
DOCUMENT NUMBER: 143:466081
TITLE: Process for the preparation of olanzapine form-I
INVENTOR(S): Chava, Satyanarayana; Gorantla, Seeta Ramanjaneyulu; Abbineni, Jyothi Basu
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005107375	A2	20051117	WO 2005-IN98	20050404
WO 2005107375	A3	20060406		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2004CH00416	A	20060519	IN 2004-CH416	20040506
PRIORITY APPLN. INFO.:			IN 2004-CH416 A	20040506

AB The present invention provides a reproducible, novel, com. feasible process to obtain olanzapine Form-I of substantial polymorphic purity with minimal number of steps using minimal number of solvents by condensation of 4-Aminomethyl-10H-thieno[2,3-b][1,5] benzodiazepine hydrochloride with N-Me piperazine followed by isolation of olanzapine methylene chloride solvate and conversion of the same to Olanzapine Form-I.

IT 67-63-0, Isopropanol, uses 67-68-5, DMSO, uses
108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of olanzapine polymorphism through olanzapine methylene chloride solvate)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



IT 75-09-2, Methylene chloride, reactions
RL: NUU (Other use, unclassified); RCT (Reactant); RACT (Reactant or reagent); USES (Uses)
(preparation of olanzapine polymorphism through olanzapine methylene chloride solvate)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1P, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of olanzapine polymorphism through olanzapine methylene chloride solvate)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 24 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1132789 CAPLUS
DOCUMENT NUMBER: 143:379779
TITLE: Marker detection method and apparatus to monitor drug compliance
INVENTOR(S): Melker, Richard J.; Dennis, Donn Michael; Prokai, Laszlo
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 722,620.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005233459	A1	20051020	US 2005-97647	20050401
US 2004081587	A1	20040429	US 2003-722620	20031126
US 2005054942	A1	20050310	US 2004-788501	20040226
EP 1718971	A2	20061108	EP 2005-756623	20050228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.:

US 2003-722620	A2	20031126
US 1999-164250P	P	19991108
US 2000-708789	B1	20001108
US 2002-54619	A2	20020122
US 2002-178877	A2	20020624
US 2004-788501	A	20040226
WO 2005-US6355	W	20050228

AB The invention includes systems and methods for monitoring therapeutic drug concentration in blood by detecting markers, such as odors, upon exhalation by a patient after the drug is taken, wherein such markers result either directly from the drug itself or from an additive combined with the drug. In the case of olfactory markers, the invention preferably utilizes electronic sensor technol., such as the com. devices referred to as "artificial" or "electronic" noses or tongues, to noninvasively monitor drug levels in blood. The invention further includes a reporting system capable of tracking drug concns. in blood (remote or proximate locations) and providing the necessary alerts with regarding to ineffective or toxic drug dosages in a patient.

IT 67-68-5, Dimethyl sulfoxide, biological studies
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(marker detection method and apparatus to monitor drug compliance)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



IT 132539-06-1, Zyprexa

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(marker detection method and apparatus to monitor drug compliance)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 25 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1042253 CAPLUS
DOCUMENT NUMBER: 143:332562
TITLE: Synthesis of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) and salts
INVENTOR(S): Mesar, Tomaz; Copar, Anton; Sturm, Hubert; Ludescher, Johannes
PATENT ASSIGNEE(S): Lek Pharmaceuticals D.D., Slovenia
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090359	A2	20050929	WO 2005-EP2876	20050317
WO 2005090359	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
SI 21747	A	20051031	SI 2004-79	20040318
AU 2005223338	A1	20050929	AU 2005-223338	20050317
CA 2558654	A1	20050929	CA 2005-2558654	20050317
EP 1749010	A2	20070207	EP 2005-716177	20050317
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
BR 2005007584	A	20070703	BR 2005-7584	20050317
IN 2006CN03389	A	20070615	IN 2006-CN3389	20060918

PRIORITY APPLN. INFO.:
SI 2004-79 A 20040318
SI 2004-311 A 20041116
WO 2005-EP2876 W 20050317

OTHER SOURCE(S): MARPAT 143:332562

AB The invention relates to a new process for the preparation of salts of olanzapine and transformation thereof into a pharmaceutically acceptable pure and discolored final product. The present invention also relates to new processes for the preparation of pure olanzapine. Thus, olanzapine was converted to its fumarate salt by reaction with fumaric acid in iso-PrOH.

IT 67-68-5, uses 68-12-2, Dimethylformamide, uses 75-05-8, Acetonitrile, uses 108-88-3, uses 109-99-9, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of olanzapine and salts)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

IT 132539-06-1P, Olanzapine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of olanzapine and salts)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L12 ANSWER 26 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1004752 CAPLUS
DOCUMENT NUMBER: 143:311947
TITLE: Isopropanol water solvate of olanzapine
INVENTOR(S): Kotar-Jordan, Berta; Lenarsic, Roman; Grcman, Marija; Smrkolj, Matej; Meden, Anton; Simonic, Igor; Zupet, Rok; Gnidovec, Joze; Benkic, Primoz
PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085256	A1	20050915	WO 2005-EP2389	20050307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21746	A	20051031	SI 2004-73	20040308
DE 102004060412	A1	20060706	DE 2004-102004060412	20041214
CA 2557986	A1	20050915	CA 2005-2557986	20050307
EP 1730153	A1	20061213	EP 2005-707723	20050307
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
NO 2006004484	A	20061129	NO 2006-4484	20061003
IN 2006CN03716	A	20070615	IN 2006-CN3716	20061009

PRIORITY APPLN. INFO.:

SI 2004-73	A	20040308
DE 2004-102004060412	A	20041214
WO 2005-EP2389	W	20050307

AB The invention relates to a novel and well defined solvate form of olanzapine which contains 2 mols. of water and 1 mol. of isopropanol per 2 mols. of olanzapine, and which can be converted into other, forms of olanzapine, in particular form I of olanzapine, as well as processes for preparing form I olanzapine.
IT 132539-06-1, Olanzapine
RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(polymorphism; prepn of isopropanol water solvates of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, Isopropanol, uses 67-68-5, Dimethylsulfoxide, uses 75-09-2, Dichloromethane, uses 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(prepn of isopropanol water solvates of olanzapine)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



IT 132539-06-1DP, Olanzapine, methylene chloride hemisolvate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn of isopropanol water solvates of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of isopropanol water solvates of olanzapine
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:962265 CAPLUS
DOCUMENT NUMBER: 143:235359
TITLE: Process for the preparation of olanzapine form 1 useful as antipsychotic drug
INVENTOR(S): Rammohan Rao, Davuluri; Dwivedi, Shriprakash Dhar; Sreenivasulu, Pamujula; Sasi Kiran, Surapaneni
PATENT ASSIGNEE(S): Neuland Laboratories Limited, India
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080401	A1	20050901	WO 2004-IN210	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2004CH00128	A	20060203	IN 2004-CH128	20040219
EP 1716154	A1	20061102	EP 2004-770670	20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2007072845	A1	20070329	US 2005-557650	20051118
PRIORITY APPLN. INFO.:			IN 2004-CH128 A	20040219
			WO 2004-IN210 W	20040716

AB This invention provides an improved process for the preparation of Olanzapine Form (I). More specially, the invention provides in-situ improved process for the direct preparation of crystalline form of Olanzapine Form (I). The present invention also provides highly pure Olanzapine Form I with single individual impurity less than 0. 1 % by HPLC. The process comprises: (1) refluxing a mixture of 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride, N-methylpiperazine, DMSO,and toluene at 110-130°, (2) cooling the reaction mixture to 20-90°, (3) adding water to the cooled mixture, (4) cooling the resulting mixture to (-10)-30°, (5) filtering the mixture, (6) slurring the resulting wet cake with water at 50-90°, (7) filtering the material and sucking dry, (8) repeating the steps 6 to 7 till the traces of DMSO and its odor are removed, (9) dissolving the resulting wet cake in a chlorinated solvent at 25-30°, (10) separating the aqueous layer, (11) stirring the organic layer with anhydrous Na2SO4 or anhydrous MgSO4, (12) filtering and washing with CH2Cl2, (13) repeating the steps (11) and (12) till the moisture content is ≤ 0.1 %, and (14) purging dry ammonia gas in CH2Cl2 layer to get polymorphic form of Olanzapine form I. The process continues as follows; (15) removing the MgSO4 from the reaction mixture and washing the salts with CH2Cl2, (16) refluxing the CH2Cl2 layer, (17) concentrating the reaction mixture

under vacuum, (18) cooling the reaction mixture to a temperature, (19) stirring the material at 0-5°, (20) filtering the material and washing with chilled CH2Cl2, (21) air drying the material, and (22) vacuum drying the product at 60-70°.

IT 67-68-5, DMSO, uses 75-09-2, Methylene chloride, uses 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of olanzapine form 1 useful as antipsychotic drug)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



IT 132539-06-1P, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of olanzapine form 1 useful as antipsychotic drug)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:638703 CAPLUS
DOCUMENT NUMBER: 143:139194
TITLE: Buccal dosage forms for extended drug release
INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Singh, Sukhjeet
PATENT ASSIGNEE(S): Panacea Biotec Ltd., India
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065640	A1	20050721	WO 2005-IN3	20050105
WO 2005065640	A8	20051208		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IN 2004DE00024	A	20060210	IN 2004-DE24		20040106
PRIORITY APPLN. INFO.:			IN 2004-DE24	A	20040106
			IN 2004-DE26	A	20040106

AB Buccal dosage form compns., preferably of poorly bioavailable drug(s), or drug(s) which undergo extensive presystematic metabolism, are provided. The compns. provide extended release of the drug in the oral cavity, and are preferably in the taste masked form. A process of preparing of such compns. is also provided. Thus, a tablet contained sumatriptan succinate 25.0, Indion-204 75.0, maltodextrin 48.0, sucrose 30.0, CM-cellulose 18.0, HPMC 8.0, HPC 8.0, citric acid 15.0, NaCl 5.0, and Povidone 3.0 25 mg/tablet.

IT 67-63-0, Isopropanol, uses
RL: NUU (Other use, unclassified); USES (Uses)
(buccal dosage forms for extended drug release)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal dosage forms for extended drug release)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:612306 CAPLUS
DOCUMENT NUMBER: 143:115577
TITLE: Condensation method for preparing olanzapine from 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine and N-methylpiperazine
INVENTOR(S): Dolitzky, Benzion; Diller, Dov
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005063771	A1	20050714	WO 2004-US43159		20041222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2551806	A1	20050714	CA 2004-2551806		20041222
US 2005159408	A1	20050721	US 2004-20869		20041222
EP 1611139	A1	20060104	EP 2004-815261		20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1906201	A	20070131	CN 2004-80040481		20041222
JP 2007515428	T	20070614	JP 2006-545605		20041222
PRIORITY APPLN. INFO.:			US 2003-532126P	P	20031222
			US 2004-547901P	P	20040225
			US 2004-561871P	A	20040412
			WO 2004-US43159	W	20041222

OTHER SOURCE(S): CASREACT 143:115577

AB A method of synthesizing olanzapine comprises: (1) heating a reaction mixture of N-methylpiperazine and 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine (i.e., thienobenzodiazepine) to about 110-145°; (2) maintaining the reaction mixture at about 110-145° for ≥5 h; (3) cooling the reaction mixture; (4) adding water, at least two organic solvents, or water and at least one organic solvent until olanzapine ppts.; (5) and collecting the olanzapine.

IT 132539-06-1P, Olanzapine
RL: IMF (Industrial manufacture); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
(condensation method for preparing olanzapine from 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine and N-methylpiperazine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(CA INDEX NAME)



IT 67-68-5, Dmso, uses 68-12-2, Dmf, uses 75-05-8
, Acetonitrile, uses 108-88-3, Toluene, uses 109-99-9,
Thf, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; condensation method for preparing olanzapine from
4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine and
N-methylpiperazine)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 30 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:472001 CAPLUS
DOCUMENT NUMBER: 143:13358
TITLE: Olanzapine containing transdermal drug delivery compositions
INVENTOR(S): Gordon, Ryan D.
PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049090	A2	20050602	WO 2004-US36439	20041102
WO 2005049090	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291043	A1	20050602	AU 2004-291043	20041102
CA 2546200	A1	20050602	CA 2004-2546200	20041102
EP 1684734	A2	20060802	EP 2004-819044	20041102
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007511605	T	20070510	JP 2006-541215	20041102
US 2007148218	A1	20070628	US 2006-579604	20060517
PRIORITY APPLN. INFO.:			US 2003-523186P P	20031118
			WO 2004-US36439 W	20041102

AB The invention features compns. for the transdermal administration of olanzapine. The compns. include olanzapine or a pharmaceutically acceptable salt thereof, a pressure sensitive adhesive, and an excipient, such as a permeation enhancer and/or a solubilizer of olanzapine. The compns. are useful for the treatment of certain psychiatric disorders, for example schizophrenia and bipolar mania.

IT 67-68-5, Dimethylsulfoxide, biological studies
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(olanzapine containing transdermal drug delivery compns.)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



IT 132539-06-1, Olanzapine

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(olanzapine containing transdermal drug delivery compns.)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 31 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:71078 CAPLUS
DOCUMENT NUMBER: 142:183422
TITLE: Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
INVENTOR(S): Thanoo, B. C.; Murtagh, Jim; Johns, Gonto
PATENT ASSIGNEE(S): Oakwood Laboratories, L.L.C., USA
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005007122	A2	20050127	WO 2004-US23324	20040719
WO 2005007122	A3	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533314	A1	20050127	CA 2004-2533314	20040719
US 2005042294	A1	20050224	US 2004-894956	20040719
EP 1660039	A2	20060531	EP 2004-778698	20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-488573P P 20030718
WO 2004-US23324 W 20040719

AB Polymer and drug containing compns. and method of preparing such compns. are disclosed. The dispersed phase formulation has a polymer, a pharmaceutically or biol. active agent and a small fraction of low pKa acid additive. Stable, filter sterilizable, non-gelling solns. containing e.g. GnRH analogs at least at levels typically used in sustained release formulations and a method of increasing solubility of a high level of a GnRH analog or a freeze-dried antagonist of GnRH in a polymer containing solution are also disclosed. The amount of the acid additive in the polymer solution is such that it is sufficient to increase the solubility of the high level of the GnRH analog in the polymer solution without affecting the release characteristics of the microspheres prepared therefrom. For example, control of mol. weight (MW) reduction of PLGA in dispersed phase with or without leuprolide was studied. There was reduction in MW upon incubating the dispersed phase consisting of RG503H, dichloromethane (DCM), and MeOH. The presence of lactic acid, glycolic acid, and oligomer acids reduced the reduction in MW. Under the exptl. conditions, acids with very low pKa, such as lactic (pKa 3.08) and glycolic (pKa 3.83) acids were more effective in preventing MW reduction caused by methanol. Even with a fraction of the acid (less than or equal to 1 mol% to that of the nucleophilic compound,

methanol) in the dispersed phase, there was influence on the mol. weight reduction There was a considerable reduction in the mol. weight of the polymer in the dispersed phase containing leuprolide. Again, presence of lactic acid, glycolic acid, and oligomer acids reduced the extent of mol. weight reduction, much more efficiently compared to acetic acid.

IT 67-63-0, Isopropanol, uses 67-68-5, Dimethylsulfoxide, uses 68-12-2, Dimethylformamide, uses 75-09-2, Dichloromethane, uses 109-99-9, Tetrahydrofuran, uses
RL: NUU (Other use, unclassified); USES (Uses)
(sustained-release compns. comprising polymer matrix and acid additive for preventing polymer mol. weight reduction, impurity formation and gelling in presence of nucleophile)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sustained-release compns. comprising polymer matrix and acid additive for preventing polymer mol. weight reduction, impurity formation and gelling in presence of nucleophile)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 32 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:14214 CAPLUS
DOCUMENT NUMBER: 142:114054
TITLE: Preparation of pyrazolo[3,4-b]pyridin-6-ones as GSK-3 kinase inhibitors
INVENTOR(S): Wager, Travis T.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000303	A1	20050106	WO 2004-IB1989	20040614
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2529083	A1	20050106	CA 2004-2529083	20040614
EP 1641454	A1	20060405	EP 2004-736777	20040614
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004011891	A	20060829	BR 2004-11891	20040614
JP 2007516169	T	20070621	JP 2006-516555	20040614
US 2005026946	A1	20050203	US 2004-874962	20040623
MX 2005PA14201	A	20060224	MX 2005-PA14201	20051221

PRIORITY APPLN. INFO.: US 2003-483489P P 20030627
WO 2004-IB1989 W 20040614
OTHER SOURCE(S): CASREACT 142:114054; MARPAT 142:114054
GI



I

AB Title compds. I [R1-2 = H, alkyl, alkoxy, cycloalkyl, etc.; R3 = H, alkyl, alkoxy, cycloalkyl] are prepared For instance, 3,4-diphenyl-2,7-dihydropyrazolo[3,4-b]pyridin-6-one is prepared in 4 steps from

3-oxo-3-phenylpropionitrile (preparation given), tert-butylhydrazine and Et benzoylacetate. Compds. I exhibit inhibitory activity, expressed as IC50, against GSK-3 that are <10,000 nM. I are useful for treatment of diabetes, dementia, Alzheimer's Disease, stroke, schizophrenia, depression, hair loss, and cancer.

IT 132539-06-1, Olanzapine
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; preparation of pyrazolo[3,4-b]pyridin-6-ones as GSK-3 kinase inhibitors for disease treatment)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 75-05-8, Acetonitrile, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolo[3,4-b]pyridin-6-ones as GSK-3 kinase inhibitors for disease treatment)

RN 75-05-8 CAPLUS

CN Acetonitrile (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 33 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927215 CAPLUS
DOCUMENT NUMBER: 141:384322
TITLE: Preparation of polymorphic crystalline forms of the antipsychotic agent olanzapine dihydrochloride
INVENTOR(S): Petho, Janos; Barkoczy, Jozsef; Kotay Nagy, Peter; Simig, Gyula; Szent-Kirallyi, Zsuzsa
PATENT ASSIGNEE(S): Egis Gyogyszergyar Rt., Hung.
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094433	A1	20041104	WO 2004-HU42	20040422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HU 200301082	A2	20041228	HU 2003-1082	20030422
AU 2004232544	A1	20041104	AU 2004-232544	20040422
CA 2522734	A1	20041104	CA 2004-2522734	20040422
EP 1620439	A1	20060201	EP 2004-728854	20040422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1777613	A	20060524	CN 2004-80010665	20040422
JP 2006524219	T	20061026	JP 2006-506249	20040422
BG 109361	A	20060929	BG 2005-109361	20051122
US 2007004706	A1	20070104	US 2006-553908	20060911
PRIORITY APPLN. INFO.:			HU 2003-1082 A	20030422
			WO 2004-HU42 W	20040422

AB Polymorphic crystalline forms of the antipsychotic agent olanzapine dihydrochloride are presented.
IT 132539-06-1, Olanzapine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of polymorphic crystalline forms of the antipsychotic agent olanzapine dihydrochloride)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, 2-Propanol, uses 68-12-2, Dmf, uses
75-05-8, Acetonitrile, uses 109-99-9, Thf, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; in preparation of polymorphic crystalline forms of the antipsychotic
agent olanzapine dihydrochloride)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 34 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:872664 CAPLUS
DOCUMENT NUMBER: 141:355325
TITLE: Novel forms of salts, co-crystals, and solvates of olanzapine and uses in treatment of psychosis and functional bowel disorders
INVENTOR(S): Hickey, Magali Bourghol; Remenar, Julius
PATENT ASSIGNEE(S): Transform Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089313	A2	20041021	WO 2004-US9947	20040331
WO 2004089313	A3	20051124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2004078161	A1	20040916	WO 2003-US327772	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007026078	A1	20070201	US 2003-660202	20030911
WO 2004060347	A2	20040722	WO 2003-US41642	20031229
WO 2004060347	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2007015841	A1	20070118	US 2003-747742	20031229
WO 2004078163	A2	20040916	WO 2004-US6288	20040226
WO 2004078163	A3	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2006140985	A1	20060629	US 2005-541703	20050708
US 2006223794	A1	20061005	US 2005-551014	20050929

PRIORITY APPLN. INFO.:

US 2003-459501P	P	20030401
US 2003-486713P	P	20030711
US 2003-487064P	P	20030711
WO 2003-US27772	A	20030904
US 2003-660202	A	20030911
US 2003-747742	A	20031229
WO 2003-US41642	A	20031229
WO 2004-US6288	A	20040226
US 2004-548343P	P	20040227
US 2002-356764P	P	20020215
US 2002-360768P	P	20020301
US 2002-380288P	P	20020515
US 2002-384152P	P	20020531
US 2002-390881P	P	20020621
US 2002-406974P	P	20020830
US 2002-232589	A1	20020903
US 2002-426275P	P	20021114
US 2002-427086P	P	20021115
US 2002-295995	A3	20021118
US 2002-428515P	P	20021122
US 2002-429515P	P	20021126
US 2002-437516P	P	20021230
US 2003-439282P	P	20030110
US 2003-439283P	P	20030110
US 2003-441335P	P	20030121
US 2003-444315P	P	20030131
US 2003-451213P	P	20030228
US 2003-378956	A	20030303
WO 2003-US6662	A	20030303
US 2003-456027P	P	20030318
US 2003-456608P	P	20030321
US 2003-463962P	P	20030418
US 2003-449307	A2	20030530
US 2003-601092	A2	20030620
WO 2003-US19574	A	20030620
US 2003-637829	A2	20030808
WO 2003-US28982	A	20030916
US 2003-508208P	P	20031002
WO 2003-US41273	A	20031224
US 2004-747742	A1	20031229
WO 2003-US341642	A	20031229
WO 2004-US400	W	20040108
US 2004-542752P	P	20040206
WO 2004-US9947	W	20040331

AB The invention provides novel soluble forms of olanzapine including novel salts, co-crystals, and solvates of olanzapine. Novel olanzapine forms of the invention are stable, readily formulated, and exhibit improved aqueous solubility when compared to known olanzapine forms. The invention also provides novel pharmaceutical compns. comprising these novel soluble forms

and related methods of treatment. Compns. and methods of the invention are useful in the treatment of psychosis and functional bowel disorders, including irritable bowel syndrome.

IT 132539-06-1P, Olanzapine
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(novel forms of salts, co-crystals, and solvates of olanzapine and uses in treatment of psychosis and functional bowel disorders)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, Isopropanol, reactions 109-99-9, THF, reactions
RL: RGT (Reagent); RACT (Reactant or reagent)
(novel forms of salts, co-crystals, and solvates of olanzapine and uses in treatment of psychosis and functional bowel disorders)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

L12 ANSWER 35 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:780550 CAPLUS
DOCUMENT NUMBER: 141:254600
TITLE: Use of secretin in the treatment of schizophrenia
INVENTOR(S): Sheitman, Brian B.; Lieberman, Jeffrey A.; Knable, Michael B.
PATENT ASSIGNEE(S): University of North Carolina at Chapel Hill, USA; The Stanley Medical Research Institute
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004080476	A1	20040923	WO 2004-US7304		20040311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 2007154534	A1	20070705	US 2007-548685		20070202
PRIORITY APPLN. INFO.:			US 2003-453895P	P	20030312
			WO 2004-US7304	W	20040311

AB The treatment of schizophrenia by administration of secretin resulting in fewer side effects is provided. In another embodiment, secretin may be used to treat disorders associated with pos. or neg. symptoms, affective or neurocognitive symptoms, social dysfunction, behavioral disorders and/or disorganization, compulsive, impulsive or repetitive behaviors.

IT 67-68-5, DMSO, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as transdermal carrier; use of secretin in treatment of schizophrenia)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of secretin in treatment of schizophrenia)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 36 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:566619 CAPLUS
DOCUMENT NUMBER: 141:128822
TITLE: Methods for the preparation of olanzapine hydrate and solvate crystal forms
INVENTOR(S): Dolitzky, Ben Zion; Aronhime, Judith; Diller, Dov
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058773	A1	20040715	WO 2003-US41123	20031224
WO 2004058773	A9	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003300324	A1	20040722	AU 2003-300324	20031224
US 2004198721	A1	20041007	US 2003-746698	20031224
EP 1575962	A1	20050921	EP 2003-814357	20031224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2007129352	A1	20070607	US 2007-649441	20070103
PRIORITY APPLN. INFO.:			US 2002-435913P	P 20021224
			US 2003-746698	A1 20031224
			WO 2003-US41123	W 20031224

AB A series of novel crystalline olanzapine forms are prepared and described, in particular hydrated (e.g., olanzapine dihydrate) and solvated crystalline forms of olanzapine (e.g., olanzapine isobutanol solvate).

IT 132539-06-1, Olanzapine
RL: RCT (Reactant); RACT (Reactant or reagent)
(methods for the preparation of olanzapine hydrate and solvate crystal forms)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 75-09-2, Dichloromethane, uses
RL: NUU (Other use, unclassified); USES (Uses)
(methods for the preparation of olanzapine hydrate and solvate crystal forms using)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 67-68-5, DMSO, uses 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; methods for the preparation of olanzapine hydrate and solvate crystal forms)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



L12 ANSWER 37 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:546512 CAPLUS
DOCUMENT NUMBER: 141:111569
TITLE: A process for the preparation of a pharmaceutically pure polymorphic form of olanzapine
INVENTOR(S): Majka, Zbigniew; Stawinski, Tomasz
PATENT ASSIGNEE(S): Adamed Sp. Z O.O., Pol.
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056833	A1	20040708	WO 2003-IB5931	20031215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2506663	A1	20040708	CA 2003-2506663	20031215
AU 2003292452	A1	20040714	AU 2003-292452	20031215
EP 1581537	A1	20051005	EP 2003-768031	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017594	A	20051122	BR 2003-17594	20031215
CN 1729195	A	20060201	CN 2003-80106963	20031215
NO 2005003368	A	20050711	NO 2005-3368	20050711
PRIORITY APPLN. INFO.:			PL 2002-357928 A	20021220
			WO 2003-IB5931 W	20031215

AB A process for the preparation of pharmaceutically pure polymorphic form I of olanzapine comprises crystallization of olanzapine from a solution in methylene chloride, wherein before the crystallization, the solution of olanzapine in methylene chloride is treated with silica gel, preferably at reflux temperature Also disclosed is the form I of olanzapine substantially free of a chloromethyl analog.impurity of olanzapine as well as a process for removing the impurity from the polymorphic form I. Thus, 400 g olanzapine was treated with 300 mL methylene chloride and silica gel was added to the solution and the mixture heated. After cooling to 0°, the olanzapine was filtered off and shown to be 99.92% pure.

IT 75-09-2, Methylene chloride, uses
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
(process for preparation of pharmaceutically pure polymorphic form of olanzapine)

RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1P, Olanzapine
RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for preparation of pharmaceutically pure polymorphic form of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 38 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:443999 CAPLUS
DOCUMENT NUMBER: 142:192430
TITLE: Fatal blood and tissue concentrations of more than 200 drugs
AUTHOR(S): Musshoff, F.; Padosch, S.; Steinborn, S.; Madea, B.
CORPORATE SOURCE: Institute of Legal Medicine, Rheinische Friedrich-Wilhelms-University, Bonn, 53111, Germany
SOURCE: Forensic Science International (2004), 142(2-3), 161-210
CODEN: FSINDR; ISSN: 0379-0738
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fatal drug concns. in body fluids and tissue samples are presented for more than 200 drugs and chems. of toxicol. interest. Addnl., a reference list is added with more than 600 original papers concerning intoxications with a lethal outcome. The data can be helpful for the interpretation and plausibility control in own cases of intoxication. However, they should be used with caution, because use of drug data without sufficient knowledge about the patient or victim, the circumstances of the case, and about toxicokinetics and toxicodynamics might give a wrong interpretation in a special case.

IT 75-05-8, Acetonitrile, biological studies 75-09-2, Dichloromethane, biological studies 132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); ANT (Analyte); ANST (Analytical study); BIOL (Biological study)
(fatal blood and tissue concns. of more than 200 drugs in humans)

RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 615 THERE ARE 615 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:433684 CAPLUS
DOCUMENT NUMBER: 140:429037
TITLE: High viscosity liquid controlled drug delivery system and medical or surgical device
INVENTOR(S): Gibson, John W.; Miller, Stacey S.; Middleton, John C.; Tipton, Arthur J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 699,002.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004101557	A1	20040527	US 2002-316441	20021210
US 5747058	A	19980505	US 1995-474337	19950607
EP 1525858	A1	20050427	EP 2005-75143	19960607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1781555	A	20060607	CN 2005-10104020	19960607
US 6413536	B1	20020702	US 1999-385107	19990827
US 7053209	B1	20060530	US 2000-699002	20001026
AU 2003200423	A1	20030410	AU 2003-200423	20030207
WO 2004052336	A2	20040624	WO 2003-US39311	20031210
WO 2004052336	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003297848	A1	20040630	AU 2003-297848	20031210
AU 2006203112	A1	20060810	AU 2006-203112	20060720
JP 2007126459	A	20070524	JP 2006-304264	20061109

PRIORITY APPLN. INFO.:		
US 1995-474337	A2	19950607
US 1995-478450	B2	19950607
US 1997-944022	A2	19970915
US 1999-385107	A3	19990827
US 2000-699002	A2	20001026
CN 1996-195895	A3	19960607
EP 1996-921521	A3	19960607
JP 1997-502181	A3	19960607
AU 1998-94750	A3	19980908
US 2002-316441	A	20021210
AU 2003-200423	A3	20030207
WO 2003-US39311	W	20031210

AB The present invention relates to novel nonpolymeric compds. and compns. that form liquid, high viscosity materials suitable for the delivery of biol. active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to

form a material of lower viscosity, rendering the material easy to administer. This solvent may be water insol. or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material. 1,6-Hexanediol lactate ε-hydroxycaproic acid produced in was dissolved in N-methylpyrrolidone at a weight ratio of 70:30. Bupivacaine base (10%) was then added to this mixture Drops weighing approx. 100 mg were precipitated into 40 mL buffer. At 4 h, around 4.1 weight% of the bupivacaine contained in the precipitated drop had been released. At 24 h, around 8.6 weight% of the bupivacaine had been released.

IT 67-68-5, DMSO, biological studies 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(high viscosity liquid controlled drug delivery system and medical or surgical device)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 40 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:203552 CAPLUS
DOCUMENT NUMBER: 140:253583
TITLE: Process of preparation of olanzapine form I
INVENTOR(S): Patel, Hiren V.; Ray, Anup K.; Patel, Pramod B.; Patel, Mahendra R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 160,958.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004048854	A1	20040311	US 2003-449643	20030530
PRIORITY APPLN. INFO.:			US 2002-160958	A2 20020531

OTHER SOURCE(S): CASREACT 140:253583

AB Disclosed is a process for the preparation of polymorph form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) by reacting (a) reacting 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride and 1-methylpiperazine in an aprotic high boiling solvent or mixts. thereof at a temperature of between about 90 to 130°.; (b) purifying the product of step (a) in an acidic medium; (c) basifying the product of step (b) to a pH of between 7.5-9; and (d) extracting the product of step (c) using a low boiling organic solvent. Olanzapine is known as an antipsychotic agent and polymorph form I is in pharmaceutical formulations.

IT 132539-06-1P, Olanzapine
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process of preparation of olanzapine polymorph form I by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride and 1-methylpiperazine)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-68-5, Dimethyl sulfoxide, uses 68-12-2, Dimethylformamide, uses 75-09-2, Dichloromethane, uses

108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvent; process of preparation of olanzapine polymorph form I by reacting 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride and 1-methylpiperazine)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



L12 ANSWER 41 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:60321 CAPLUS
DOCUMENT NUMBER: 140:117363
TITLE: Preparation of polymorphic forms of olanzapine from its solvates
INVENTOR(S): Kotar, Jordan Berta; Vrecer, Franc; Grcman, Marija
PATENT ASSIGNEE(S): Krka, D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006933	A2	20040122	WO 2003-SI24	20030714
WO 2004006933	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21270	A	20040229	SI 2002-175	20020715
CA 2493370	A1	20040122	CA 2003-2493370	20030714
AU 2003256242	A1	20040202	AU 2003-256242	20030714
EP 1551414	A2	20050713	EP 2003-764287	20030714
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006040920	A1	20060223	US 2005-521646	20050113
NO 2005000720	A	20050210	NO 2005-720	20050210
IN 2005CN00184	A	20070330	IN 2005-CN184	20050214

PRIORITY APPLN. INFO.: SI 2002-175 A 20020715
WO 2003-SI24 W 20030714

AB The invention relates to a process for the preparation of form I of olanzapine, crystallized from a solvent mixture which comprises 2-propanol, some pseudopolymorphic forms, namely solvates of olanzapine, a new polymorphic form A of olanzapine, and processes for the preparation thereof. For example, form A of olanzapine was prepared by suspending 10.0g olanzapine in 30 mL acetonitrile, adding 35mL methylene chloride in heated suspension, and drying under vacuum at 60OC.

IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PRP (Properties); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(polymorphism; preparation of polymorphic forms of olanzapine from its solvates)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, 2-Propanol, processes 67-68-5, Dimethylsulfoxide, processes 68-12-2, N,N-Dimethylformamide, processes 75-05-8, Acetonitrile, processes 75-09-2, Methylene chloride, processes 108-88-3, Toluene, processes 109-99-9, Tetrahydrofuran, processes
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
(preparation of polymorphic forms of olanzapine from its solvates)

RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



RN 75-09-2 CAPLUS

CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 109-99-9 CAPLUS
CN Furan, tetrahydro- (CA INDEX NAME)

L12 ANSWER 42 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:875098 CAPLUS
DOCUMENT NUMBER: 139:341733
TITLE: Novel crystalline forms of celecoxib and other compounds
INVENTOR(S): Ndzie, Elias
PATENT ASSIGNEE(S): Generics [UK] Limited, UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003090730	A1	20031106	WO 2002-GB1902	20020425
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002251329	A1	20031110	AU 2002-251329	20020425
PRIORITY APPLN. INFO.:			WO 2002-GB1902 A	20020425

AB Disclosed is an organic compound in a solid crystalline form that affords the compound improved handling properties and/or improved properties as a pharmaceutical agent. The compound is preferably in the form of an adduct or solvate with an organic solvent. The compds. include celecoxib, rofecoxib, olanzapine, zafirlukast, ondansetron, clopidogrel, ticlopidine, and salts and esters thereof. For example, celecoxib DMA adduct (1:1) was prepared and its physicochem. properties, including IR spectra and x-ray diffraction pattern, were studied.

IT 67-68-5, Dimethylsulfoxide, uses
RL: NUU (Other use, unclassified); USES (Uses)
(crystalline drug solvent adducts for improved handling and physicochem. properties)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



IT 132539-06-1D, Olanzapine, organic solvent adducts
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(crystalline drug solvent adducts for improved handling and physicochem. properties)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-

(CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 43 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:154230 CAPLUS
DOCUMENT NUMBER: 138:210277
TITLE: Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
INVENTOR(S): Diamond, Scott L.; Gruneich, Jeffrey
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003015757	A1	20030227	WO 2002-US26152		20020815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2456977	A1	20030227	CA 2002-2456977		20020815
AU 2002324723	A1	20030303	AU 2002-324723		20020815
EP 1424998	A1	20040609	EP 2002-759383		20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
JP 2005525290	T	20050825	JP 2003-520717		20020815
US 2005069577	A1	20050331	US 2004-777805		20040212
PRIORITY APPLN. INFO.:			US 2001-312729P	P	20010816
			US 2002-358138P	P	20020220
			WO 2002-US26152	W	20020815

AB The invention relates to compns. and methods for a one-step synthetic technique for making cationic steroid or cationic drug mols. for use as delivery vehicles. The invention further relates to methods for using cationic steroid mols. in lipofection or transfection, delivery of drugs, and for treatment of inflamrnation and other diseases and disorders. The invention also relates to cationic steroid prodrugs and cationic prodrugs and to methods of modifying drugs.

IT 67-68-5, Dmso, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 44 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:555334 CAPLUS
DOCUMENT NUMBER: 137:114525
TITLE: Syntactic deformable pharmaceutical foam compositions
INVENTOR(S): Odidi, Isa; Odidi, Amina
PATENT ASSIGNEE(S): Can.
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002056861	A2	20020725	WO 2002-CA54	20020117
WO 2002056861	A3	20021017		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6800668	B1	20041005	US 2001-765783	20010119
CA 2435276	A1	20020725	CA 2002-2435276	20020117
CA 2435276	C	20050315		
AU 2002226223	A1	20020730	AU 2002-226223	20020117
PRIORITY APPLN. INFO.:			US 2001-765783 A	20010119
			WO 2002-CA54 W	20020117

AB The invention relates to methods for preparing a syntactic foam composition suitable for use as a carrier for chems. or other compds., including pharmaceuticals. Carbopol 971P, hydroxyethyl cellulose, cellulose microspheres and silica, was mixed in a high-shear mixer. The resulting admixt. was treated with 2-propanol, while simultaneously subjecting the admixt. to high-shear forces in the high-shear mixer. This mixing created a uniform stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying. Metoprolol succinate was added to the above admixt. and subjected to high-shear agitation for 2 min before treatment with 2-propanol. A stable syntactic deformable and compressible dendritic solid foam which could be shaped before drying was obtained. This was dried at 40°. The dried foam was the disentangled by size reduction to obtain discrete particles. The free flowing particles were reassembled and shaped by compression in a mold. The shaped units, when subjected to an aqueous medium, released metoprolol over a period of ≤3 h.

IT 67-63-0, 2-Propanol, uses
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
(syntactic deformable pharmaceutical foam compns.)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(syntactic deformable pharmaceutical foam compns.)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-
(CA INDEX NAME)



L12 ANSWER 45 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:487335 CAPLUS
DOCUMENT NUMBER: 137:68153
TITLE: Novel in-situ forming polymer-based controlled release microcarrier delivery systems
INVENTOR(S): Bhagwatwar, Harshal Prabhakar; Bapat, Varada Ramesh; Paithankar, Mahesh Balkrishna; Yeola, Bhushan Subhash; Gosavi, Arun Shriniwas; Bagool, Manoj Anil; Shetty, Nitin; Shukla, Milind Chintaman; De Souza, Noel John; Khorakiwala, Habil Fakhruddin
PATENT ASSIGNEE(S): India
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049573	A2	20020627	WO 2001-IN219	20011214
WO 2002049573	A3	20030130		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003049320	A1	20030313	US 2001-23427	20011212
CA 2436149	A1	20020627	CA 2001-2436149	20011214
AU 200222505	A	20020701	AU 2002-22505	20011214
EP 1363556	A2	20031126	EP 2001-271193	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
IN 2003MN00505	A	20070316	IN 2003-MN505	20030512

PRIORITY APPLN. INFO.: US 2000-256319P P 20001218
WO 2001-IN219 W 20011214

AB A ready-to use, stable, gelled polymer droplet-in-oil dispersion is described which helps in in-situ formation of a multitude of small solid, semisolid, or gelled microcarriers. The dispersion is placed into a body in a semisolid form and cures to form the delivery system in-situ. The process for making such a dispersion comprises the steps of (i) dissolving a polymer in a biocompatible solvent at an elevated temperature to form a polymer solution, (ii) preparing a second oil phase solution of a biocompatible emulsifier at an elevated temperature, (iii) mixing the polymer solution with the oil phase solution at an elevated temperature and subsequently cooling to refrigeration temperature Placing the gelled dispersion within a body produces the microcarrier delivery system in-situ. The composition of a syringeable, biodegradable dispersion incorporating an effective level of a biol. active agent before injection into a body provides a novel controlled delivery system of drugs for health-care applications. Thus, Poly(DL-lactide-co-glycolide) was dissolved in DMSO to form a polymer solution of a 30% weight/weight concentration To this solution was added leuprolide acetate

to form a 10% weight/weight solution of the drug with respect to the polymer. The polymer solution was injected by into a continuous oil phase comprising a 20% weight/weight solution of sorbitan monostearate (Arlacel 60) in super refined sesame seed oil maintained at 70-75°, accompanied by high speed homogenization at 13,000 rpm, for 3 min. The resulting polymer droplet-in-oil dispersion was cooled to room temperature with continuous mixing to obtain an opaque mass with a gel-like consistency, which did not flow. The gel was stored under refrigerated conditions until further use. The gel was smooth to the touch with an absence of any gritty particles. Microscopic observation of the gel revealed discrete distorted blue colored droplets of the discontinuous phase dispersed within the continuous oil phase.

IT 67-68-5, Dimethyl sulfoxide, uses 68-12-2, Dimethylformamide, uses
RL: NUU (Other use, unclassified); PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process); USES (Uses)
(in-situ forming polymer-based controlled release microcarrier delivery systems)

RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 68-12-2 CAPLUS
CN Formamide, N,N-dimethyl- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in-situ forming polymer-based controlled release microcarrier delivery systems)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Me
N
N
N
Me
S
N
H

L12 ANSWER 46 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:276280 CAPLUS
DOCUMENT NUMBER: 136:304024
TITLE: Method for determining chemical reactivity
INVENTOR(S): Wienkers, Larry C.; Hauer, Michael J.; Epps, Dennis E.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002029416	A2	20020411	WO 2001-US27754	20011005
WO 2002029416	A3	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001096234	A5	20020415	AU 2001-96234	20011005
US 2002110919	A1	20020815	US 2001-972520	20011005
US 6979545	B2	20051227		

PRIORITY APPLN. INFO.: US 2000-238238P P 20001005
WO 2001-US27754 W 20011005

AB A process for screening chemical compds. for electrophilic properties comprising the steps of: (a) providing an assay having one or more reaction vessels; (b) adding a predetd. amount of sep. chemical compds. for screening to each reaction vessel; (c) adding a predetd. amount of a surrogate chemical marker to each reaction vessel and allowing said sep. chemical compds. and surrogate chemical marker to incubate for a period of time;
(d) adding a reactive chemical to each reaction vessel which is capable of reacting with residual surrogate chemical marker such that the amount of residual surrogate chemical marker present after step (c) can be quant. or qual. measured; and (e) quant. or qual. measuring said residual chemical marker is provided. In particular, the invention provides a high throughput toxicity screening method for pharmaceutically active mols.

IT 108-88-3, Toluene, biological studies 132539-06-1, Olanzapine
RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL (Biological study)
(method for determining chemical electrophilic reactivity using reactive chems.
and surrogate chemical markers using solvents in relation to drug toxicity screening)

RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 75-05-8, Acetonitrile, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solvent; method for determining chemical electrophilic reactivity using reactive chems. and surrogate chemical markers in solvents in relation to drug toxicity screening)
RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)



IT 67-68-5, DMSO, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(solvent; method for determining chemical electrophilic reactivity using reactive chems. and surrogate chemical markers using solvents in relation to drug toxicity screening)
RN 67-68-5 CAPLUS
CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



L12 ANSWER 47 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:171904 CAPLUS
DOCUMENT NUMBER: 136:221739
TITLE: Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
INVENTOR(S): Koprowski, Robert; Reguri, Buchi Reddy; Chakka, Ramesh
PATENT ASSIGNEE(S): Reddy's Laboratories Ltd., India
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018390	A1	20020307	WO 2001-US7258	20010307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IN 190895	A1	20030830	IN 2000-MA711	20000831
IN 191714	A1	20031220	IN 2000-MA709	20000831
CA 2420987	A1	20020307	CA 2001-2420987	20010307
AU 200143475	A	20020313	AU 2001-43475	20010307
EP 1313742	A1	20030528	EP 2001-916449	20010307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001014031	A	20030909	BR 2001-14031	20010307
HU 200300875	A2	20031229	HU 2003-875	20010307
JP 2004507548	T	20040311	JP 2002-523905	20010307
NO 2003000926	A	20030424	NO 2003-926	20030227
ZA 2003001640	A	20040203	ZA 2003-1640	20030227
MX 2003PA01827	A	20041101	MX 2003-PA1827	20030228
US 2004067936	A1	20040408	US 2003-363436	20031120
PRIORITY APPLN. INFO.:			IN 2000-MA709 A	20000831
			IN 2000-MA711 A	20000831
			WO 2001-US7258 W	20010307

AB The present invention relates to a method for the preparation of hydrates of olanzapine. The present invention also relates to a process for conversion of these hydrates into a pure crystalline form of olanzapine referred to as form-1. The present invention also relates to a method of converting olanzapine form-2 to form-1. Thus, a mixture of 4-amino-2-methyl-10H-thieno-[2,3-b][1,5]benzodiazepine-HCl, N-methylpiperazine, DMSO, and toluene was heated under reflux, the mixture was cooled, and water was added. The olanzapine that was separated was dried to give a product with a moisture content of 5.22%.

IT 67-68-5, DMSO, uses 75-09-2, Methylene chloride, uses 108-88-3, Toluene, uses
RL: NUU (Other use, unclassified); USES (Uses)
(preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine)

RN 67-68-5 CAPLUS

CN Methane, 1,1'-sulfinylbis- (CA INDEX NAME)



RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



RN 108-88-3 CAPLUS
CN Benzene, methyl- (CA INDEX NAME)



IT 132539-06-1P, Olanzapine
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 48 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:725436 CAPLUS
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406
CA 2366702	A1	20001012	CA 2000-2366702	20000316
EP 1165048	A1	20020102	EP 2000-916547	20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 67-63-0, Isopropanol, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solubilizer; pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)
RN 67-63-0 CAPLUS
CN 2-Propanol (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 49 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:400460 CAPLUS
DOCUMENT NUMBER: 127:70833
TITLE: Solvate of olanzapine
INVENTOR(S): Larsen, Samuel D.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA; Lilly Industries Ltd.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5637584	A	19970610	US 1995-410263	19950324
PRIORITY APPLN. INFO.:			US 1995-410263	19950324

AB A methylene chloride solvate of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (I) which is useful for the desired anhydrous form is provided. Thus, 5.0 g of tech. grade I was suspended in methylene chloride and heated to about 30° for 30 min, then chilled to 5° and the product thus obtained was isolated by vacuum filtration.

IT 75-09-2, Methylene chloride, uses
RL: NUU (Other use, unclassified); USES (Uses)
(solvate of olanzapine)
RN 75-09-2 CAPLUS
CN Methane, dichloro- (CA INDEX NAME)



IT 132539-06-1, Olanzapine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solvate of olanzapine)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



L12 ANSWER 50 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1997:324780 CAPLUS
DOCUMENT NUMBER: 127:5106
TITLE: Preparation of 2-methylthienobenzodiazepine as central nervous system agent.
INVENTOR(S): Chakrabarti, Jiban K.; Hotten, Terrence M.; Tupper, David E.
PATENT ASSIGNEE(S): Lilly Industries Ltd., UK
SOURCE: U.S., 11 pp., Cont.-in-part of U.S. Ser. No. 44,844, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5627178	A	19970506	US 1995-387997	19950213
US 5229382	A	19930720	US 1992-890348	19920522
US 5817655	A	19981006	US 1996-748292	19961113
US 6008216	A	19991228	US 1998-122294	19980724

PRIORITY APPLN. INFO.:

US 1991-690143	B1	19910423
US 1992-890348	A2	19920522
US 1993-44844	B2	19930408
GB 1990-9229	A	19900425
US 1995-387997	A2	19950213
US 1996-748292	A3	19961113

GI



I

AB 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine (I), or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. Compound I is used in the treatment of schizophrenia, catatonic, delusional disorder, brief reactive psychosis, manic depression, anxiety disorder, post-traumatic stress disorder, obsessive compulsive disorder, delusions, hallucinations, and disorganized behavior. Thus, 4.3g of 4-amino-2-methyl-10H-thieno[2,3-b]benzodiazepine hydrochloride (preparation given) was reluxed in a mixture of 15 mL of N-methylpiperazine, DMSO, and toluene for 20 h to give 1.65g I. Formulations containing I were described.

IT 132539-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-methyl-thieno-benzodiazepine as central nervous system agent)

RN 132539-06-1 CAPLUS

CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 68-12-2, Dimethylformamide, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 2-methyl-thieno-benzodiazepine as central nervous system agent)

RN 68-12-2 CAPLUS

CN Formamide, N,N-dimethyl- (CA INDEX NAME)



L12 ANSWER 51 OF 51 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:383592 CAPLUS
DOCUMENT NUMBER: 122:197139
TITLE: Comparison of theory-based and empirical modeling for the prediction of chromatographic behavior in the ion-pairing separation of benzodiazepine-derived pharmaceutical compounds
AUTHOR(S): Larew, Larry A.; Olsen, Bernard A.; Stafford, John D.; Wilhelm, Melinda V.
CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, P.O. Box 685, Drop Code TL12, Lafayette, IN, 47902, USA
SOURCE: Journal of Chromatography, A (1995), 692(1 + 2), 183-93
CODEN: JCRAEY; ISSN: 0021-9673
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Two approaches were examined for predicting chromatog. behavior during the reversed-phase ion-pairing separation of benzodiazepine-derived pharmaceutical compds. The capacity factor for olanzapine and its resolution from a closely related compound, desmethylolanzapine, were studied as a function of the percentage of acetonitrile, the ion-pairing reagent concentration and the buffer pH. In the first approach, the results were analyzed using the theory-based software package DryLab I/mp. In the second approach, statistical anal. was used to derive empirical equations to predict the dependence of the chromatog. behavior on each of the exptl. variables. At the lowest ion-pairing reagent concentration, DryLab I/mp was found to be a poor predictor of resolution For this complex separation, the empirical equations derived from the statistical anal. were found to predict better the chromatog. behavior over the ranges tested. These equations were used to generate response-surface plots to evaluate the method ruggedness.

IT 132539-06-1, Olanzapine
RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
(modeling of chromatog. behavior in ion-pairing separation of benzodiazepine derivs.)
RN 132539-06-1 CAPLUS
CN 10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



IT 75-05-8, Acetonitrile, uses

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(modeling of chromatog. behavior in ion-pairing separation of benzodiazepine derivs.)

RN 75-05-8 CAPLUS
CN Acetonitrile (CA INDEX NAME)